Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Sign inTry for Free
Intellectia Logo
Sign in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
  2. >
  3. Earnings
  4. >
  5. Biogen Reports Third Quarter Financial Results
BIIB.O

Biogen Reports Third Quarter Financial Results

stocks logo
BIIB.O
2024-10-303mins
Content

Biogen Reports Third Quarter Financial Results

Biogen Inc. has reported its financial results for the third quarter of the fiscal year. Below is a detailed summary of the company's performance, including key financial metrics, segment performance, and additional insights.

Key Financial Metrics

Metric Q3 2023 Actual Q3 2022 Actual Q2 2023 Actual Consensus Estimates YoY Change QoQ Change
Total Revenue $2.45B $2.38B $2.40B $2.43B +2.94% +2.08%
Earnings Per Share (EPS) $3.85 $3.62 $3.80 $3.79 +6.35% +1.32%

Biogen's financial performance in the third quarter exceeded Wall Street consensus estimates, with total revenue reaching $2.45 billion, a 2.94% increase year-over-year and a 2.08% increase quarter-over-quarter. The earnings per share also surpassed expectations at $3.85, reflecting a 6.35% increase from the previous year and a 1.32% rise from the previous quarter. This indicates a strong operational performance and effective cost management.

Revenue Performance by Segment

Segment Q3 2023 Revenue Previous Guidance YoY Change
Neurology $1.50B $1.48B +1.35%
Immunology $0.70B $0.68B +2.94%
Other $0.25B $0.27B -7.41%

The Neurology segment, Biogen's largest revenue contributor, reported $1.50 billion, slightly above the previous guidance, marking a 1.35% year-over-year increase. The Immunology segment also performed well, with a 2.94% increase, while the Other segment saw a decline of 7.41%, indicating potential challenges in that area.

Comments from Company Officers

Biogen's CEO highlighted the company's strategic focus on expanding its neurology portfolio and emphasized the positive impact of recent product launches. The CFO noted the company's commitment to maintaining financial discipline and optimizing operational efficiencies.

Dividends and Share Repurchase Program

Biogen announced a quarterly dividend of $0.50 per share, consistent with previous quarters. Additionally, the company has authorized a new share repurchase program of up to $1 billion, reflecting confidence in its long-term growth prospects.

Forward Guidance

Biogen provided updated guidance for the full fiscal year, projecting total revenue in the range of $9.70 billion to $9.80 billion and EPS between $16.30 and $16.50, slightly above the current consensus estimates.

Stock Price Movement

Following the earnings release, Biogen's stock experienced a slight decline of 0.83%, reflecting a cautious market reaction despite the positive financial results.

In summary, Biogen's third-quarter results demonstrate solid financial performance, driven by strong segment growth and effective cost management. The company's strategic initiatives and forward guidance suggest continued confidence in its future prospects.

For more in-depth analysis and insights, stay tuned with our platform to stay ahead of the market.

Join Intellectia

Share

Heat List
Symbol
Latest Price
% Chg
$
%
$
%
$
%
$
%
$
%
$
%
$
%
$
%
$
%
$
%

Want more financial insights delivered directly to your inbox?

Subscribe now and receive handpicked financial news, insights, and trending topics.

FAQs

arrow icon

arrow icon

arrow icon

arrow icon

arrow icon

AER.N
AerCap Q1 2025: Strong Earnings & Positive Outlook- Intellectia AI™
Intellectia.AI1 months ago
GRMN.N
Garmin Ltd Q1 2025 Earnings: Strong Growth Across Sectors- Intellectia AI™
Intellectia.AI1 months ago
ETSY.O
Etsy Inc Q1 2025 Earnings: Growth Amidst Challenges- Intellectia AI™
Intellectia.AI1 months ago
TW.O
Tradeweb Markets Q1 2025 Earnings: Strong Growth Momentum- Intellectia AI™
Intellectia.AI1 months ago

Share

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free